AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
IXICO plc
Video analysis: PHYOF
All videosNo video analysis for this stock yet. Request one from our team.
News: PHYOF
IXICO guidance unchanged after Huntington's cancellations
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a neuroscience imaging and biomarker analytics company, has confirmed its revenue guidance remains unchanged after...
IXICO guidance unchanged after Huntington's cancellations
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a neuroscience imaging and biomarker analytics company, has confirmed its revenue guidance remains unchanged after two clients discontinued Huntington's disease programmes it was supporting. The AIM-listed company said the cancellations would reduce its contracted order book by around £1.5 million over the next two financial years.
South32’s $4.7bn Hermosa project clears key US approval as critical minerals push accelerates
South32 Ltd (LSE:S32, ASX:S32, FRA:32Z, OTC:SHTLF, JSE:S32) has secured a major US federal approval for its US$4.7 billion Hermosa critical minerals project...
IXICO lifts revenue forecast on contract wins and wider client base - UPDATE
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging company, rose 11% to 9p after it has raised its revenue forecast for the...
IXICO lifts revenue forecast on contract wins and wider client base
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging company, has raised its revenue forecast for the current financial year after stronger-than-expected trading. The company now expects revenues of at least £8 million for the year ending 30 September 2026.